{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:21Z","timestamp":1791475521730,"version":"4.3.4"},"reference-count":35,"publisher":"Japanese Society of Internal Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.2169\/internalmedicine.3773-24","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T22:11:00Z","timestamp":1727993460000},"page":"1303-1314","source":"Crossref","is-referenced-by-count":5,"title":["Roxadustat for Treating Anemia in Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis: A Retrospective Study"],"prefix":"10.2169","volume":"64","author":[{"given":"Masanori","family":"Tamaki","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"},{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taizo","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Minato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tamaki Aozora Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"},{"name":"Department of Nephrology, Shizuoka General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wakino","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokushima University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32: S133-S141, 1998.","DOI":"10.1016\/S0272-6386(98)70176-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 66: 1131-1138, 2004.","DOI":"10.1111\/j.1523-1755.2004.00863.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Akizawa T, Okumura H, Alexandre AF, Fukushima A, Kiyabu G, Dorey J. Burden of anemia in chronic kidney disease patients in Japan: a literature review. Ther Apher Dial 22: 444-456, 2018.","DOI":"10.1111\/1744-9987.12712"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47: S11-S145, 2006.","DOI":"10.1053\/j.ajkd.2006.03.011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Seliger S, Fox KM, Gandra SR, et al. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol 5: 882-888, 2010.","DOI":"10.2215\/CJN.07171009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000, 1989.","DOI":"10.7326\/0003-4819-111-12-992"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006.","DOI":"10.1681\/ASN.2005090997"},{"key":"8","unstructured":"8. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 18: ii2-ii6, 2003."},{"key":"9","unstructured":"9. McMurray J, Parfrey P, Adamson JW, et al. Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: 279-335, 2012."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008.","DOI":"10.1038\/ki.2008.295"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Fukuma S, Yamaguchi T, Hashimoto S, et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 59: 108-116, 2012.","DOI":"10.1053\/j.ajkd.2011.07.014"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Eriguchi R, Taniguchi M, Ninomiya T, et al. Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-cohort study. J Nephrol 28: 217-225, 2015.","DOI":"10.1007\/s40620-014-0121-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Haase VH. Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev 27: 41-53, 2013.","DOI":"10.1016\/j.blre.2012.12.003"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926-1932, 2007.","DOI":"10.1172\/JCI31370"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381: 1011-1022, 2019.","DOI":"10.1056\/NEJMoa1901713"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381: 1001-1010, 2019.","DOI":"10.1056\/NEJMoa1813599"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (dolomites). Nephrol Dial Transplant 36: 1616-1628, 2021.","DOI":"10.1093\/ndt\/gfab191"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Akizawa T, Iwasaki M, Otsuka T, Yamaguchi Y, Reusch M. Phase 3 study of roxadustat to treat anemia in non-dialysis-dependant CKD. Kidney Int Rep 6: 1810-1828, 2021.","DOI":"10.1016\/j.ekir.2021.04.003"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: quo vadis. Clin J Am Soc Nephrol 5: 553-556, 2010.","DOI":"10.2215\/CJN.00490110"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 362: 189-192, 2010.","DOI":"10.1056\/NEJMp0912328"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bland JM, Altman DG. Transformations, means, and confidence intervals. BMJ 312: 1079, 1996.","DOI":"10.1136\/bmj.312.7038.1079"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yamamoto H, Nishi S, Tomo T, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther 3: 36, 2017.","DOI":"10.1186\/s41100-017-0114-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Akizawa T, Tanaka-Amino K, Otsuka T, Yamaguchi Y. Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat. Clin Exp Nephrol 26: 843-850, 2022.","DOI":"10.1007\/s10157-022-02225-w"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Meurs I, Hoekstra M, van Wanrooij EJ, et al. HDL cholesterol levels are an important factor for determining the lifespan of erythrocytes. Exp Hematol 33: 1309-1319, 2005.","DOI":"10.1016\/j.exphem.2005.07.004"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Kim H, Yun HR, Park S, et al. High serum adiponectin is associated with anemia development in chronic kidney disease: the results from the KNOW-CKD study. Cytokine 103: 1-9, 2018.","DOI":"10.1016\/j.cyto.2017.12.018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zhao B, Yang X, Li W, et al. Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study. Clin Kidney J 16: 1500-1507, 2023.","DOI":"10.1093\/ckj\/sfad080"},{"key":"#cr-split#-29.1","unstructured":"29. PMDA. Japanese Pharmaceutical and Medical Devices Agency Report on Roxadustat [Internet]. [updated 2019 Sep 4"},{"key":"#cr-split#-29.2","unstructured":"cited 2023 May 3]. Available from: https:\/\/www.pmda.go.jp\/files\/000234811.pdf."},{"key":"30","unstructured":"30. FDA. Roxadustat briefing document: cardiovascular and renal drugs advisory committee meeting [Internet]. [cited 2023 May 6]. Available from: https:\/\/www.fda.gov\/media\/150728\/download; 2021."},{"key":"31","unstructured":"31. FDA. Final summary minutes of the cardiovascular and renal drugs advisory committee meeting [Internet]. [cited 2023 May 6]. Available from: https:\/\/www.fda.gov\/media\/151422\/download; 2021."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Provenzano R, Szczech L, Leong R, et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin J Am Soc Nephrol 16: 1190-1200, 2021.","DOI":"10.2215\/CJN.16191020"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Millwood IY, Walters RG, Mei XW, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 393: 1831-1842, 2019.","DOI":"10.1016\/S0140-6736(18)31772-0"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Larsson SC, Wallin A, Wolk A, Markus HS. Differing association of alcohol consumption with different stroke types: a systematic review and meta-analysis. BMC Med 14: 178, 2016.","DOI":"10.1186\/s12916-016-0721-4"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_3773-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:00:53Z","timestamp":1746244853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/9\/64_3773-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3773-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"3773-24"}}